The differential immune responses to COVID-19 in peripheral and lung revealed by single-

cell RNA sequencing

Gang Xu<sup>1\*</sup>, Furong Qi<sup>1\*</sup>, Hanjie Li<sup>2\*</sup>, Qianting Yang<sup>1</sup>, Haiyan Wang<sup>1</sup>, Xin Wang<sup>1</sup>, Xiaoju Liu<sup>3</sup>, Juanjuan Zhao<sup>1</sup>,

Xuejiao Liao<sup>1</sup>, Yang Liu<sup>1</sup>, Ido Amit<sup>4</sup>, Lei Liu<sup>1†</sup>, Shuye Zhang<sup>5†</sup>, Zheng Zhang<sup>1,6†</sup>

Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen 518112, Guangdong Province,

<sup>1</sup>Institute for Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, The Second

China.

<sup>2</sup>Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen,

<sup>3</sup>Hepatology Unit, Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

<sup>4</sup>Department of Immunology, Weizmann Institute of Science, Rehovot, Israel

<sup>5</sup>Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China

<sup>6</sup>Lead Contact

\*These authors contributed equally.

<sup>†</sup>Correspondence:

Zheng Zhang, PhD, MD. Institute of Hepatology, Shenzhen 3<sup>rd</sup> People's Hospital, Shenzhen, Guangdong Province 518100,

China; Phone: 86-755-81238983; Fax: 86-755-81238983; Email: zhangzheng1975@aliyun.com. Shuye Zhang, PhD. Shanghai

Public Health Clinical Center and Institute of Biomedical Sciences, Fudan University, Shanghai, China; Email:

zhangshuye@shphc.org.cn. and Lei Liu, MD. Shenzhen 3<sup>rd</sup> People's Hospital, Shenzhen, Guangdong Province 518100, China;

Email: liulei3322@aliyun.com

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### Abstract

1

18

19

Understanding the mechanism that leads to immune dysfunction induced by SARS-CoV2 virus is 2 crucial to develop treatment for severe COVID-19. Here, using single cell RNA-seq, we characterized 3 the peripheral blood mononuclear cells (PBMC) from uninfected controls and COVID-19 patients, 4 and cells in paired broncho-alveolar lavage fluid (BALF). We found a close association of decreased 5 dendritic cells (DC) and increased monocytes resembling myeloid-derived suppressor cells (MDSC) 6 which correlated with lymphopenia and inflammation in the blood of severe COVID-19 patients. 7 Those MDSC-like monocytes were immune-paralyzed. In contrast, monocyte-macrophages in BALFs 8 of COVID-19 patients produced massive amounts of cytokines and chemokines, but secreted little 9 interferons. The frequencies of peripheral T cells and NK cells were significantly decreased in severe 10 COVID-19 patients, especially for innate-like T and various CD8<sup>+</sup> T cell subsets, compared to health 11 controls. In contrast, the proportions of various activated CD4<sup>+</sup> T cell subsets, including Th1, Th2 and 12 Th17-like cells were increased and more clonally expanded in severe COVID-19 patients. Patients' 13 peripheral T cells showed no sign of exhaustion or augmented cell death, whereas T cells in BALFs 14 produced higher levels of IFNG, TNF, CCL4 and CCL5 etc. Paired TCR tracking indicated abundant 15 recruitment of peripheral T cells to the patients' lung. Together, this study comprehensively depicts 16 17 how the immune cell landscape is perturbed in severe COVID-19.

**Key words:** scRNA-seg, immunopathogenesis, SARS-CoV-2, MDSC, cytokine storm

Introduction

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

The coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has been spreading rapidly worldwide, causing serious public health crisis. Although most SARS-CoV-2 infected cases have asymptomatic or mild-to-moderate diseases, around 10% of those infected may develop severe pneumonia and other associated organ malfunctions<sup>1</sup>. Old age, the male sex and underlying comorbidities are risk factors for causing severe COVID-19<sup>2</sup>, however, the pathogenesis mechanisms remains unclear. Immune perturbations were thought to play crucial roles in the COVID-19 pathogenesis. Indeed, many reports showed that lymphopenia and increased blood cytokine levels were closely associated with the development or recovery of severe COVID-19 and proposed to treat the patients by inhibiting cytokine storms<sup>3-6</sup>. Recent studies have revealed more aspects of different immune players in COVID-19 infections. Although SARS-CoV-2 infection in host cells elicits robust secretion of chemokines and cytokines, it only weakly induces the IFNs<sup>7</sup>. In our earlier studies, we showed increased recruitment of highly inflammatory FCN1<sup>+</sup> monocyte-derived macrophages in patients' BALFs, suggesting their implication in the cytokine storm <sup>8,9</sup>. Intriguingly, T and B cell responses, and neutralizing antibodies recognizing SARS-CoV-2 were detected among most of the infected patients, with higher levels in those with old age and severe diseases 10-12. The dysregulations of other immune cell compartments, such as monocytes, DCs, and innate-like T cells are also likely present in severe COVID-19 13-16. To unravel the barely known immune mechanisms underlying COVID-19 pathogenesis in an unbiased and comprehensive manner, we and others have applied the scRNA-seq to profile the immune cell heterogeneity and dynamics in BALFs, blood, and respiratory tract samples from the COVID-19 patients. Collectively, those studies revealed a stunted IFN response, depletion of NK and T lymphocytes, loss of MHC class II molecules and significantly elevated levels of chemokine production from monocytes in the patients <sup>8,9,13,14,17-19</sup>. However, a complete picture of the COVID-19 induced immune perturbation has not been generated. Here, we conducted scRNA-seq analysis of paired blood and BALF samples from the same COVID-19 patients. Our data revealed profound alterations of various immune compartments and depicted a dichotomy of peripheral immune paralysis and broncho-alveolar immune hyperactivation in COVID-19 patients.

### Results

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

severer diseases.

### The overview of dysregulated peripheral immune landscape in severe COVID-19 patients

A high-quality single-cell RNAseq dataset composed of 200, 059 cells were generated that characterized peripheral immune cells from 3 healthy controls, 5 mild and 8 severe COVID-19 patients (Figure 1A). The metadata of these patients is listed in Table 1. Patients with mild diseases were all cured and discharged after 11-18 days hospitalization, 2 of the 8 patients with severe diseases succumbed, whereas other severe cases recovered after 12-58 days hospitalization. The clinical course of this patient cohort is similar to earlier reports, where elderly patients with underlying diseases were prone to develop severe symptoms and showed higher mortality 1,2,20. In addition, the plasma levels of IL-6 and C-reactive proteins (CRP) in severe patients were higher, while lymphocyte counts were reduced, indications of both cytokine storm and lymphopenia. The clustering analysis showed 29 clusters and 10 major cell types annotated by marker genes, including T cell (CD3D), natural killer (NK) cell (KLRF1), B cell (CD79A), monocyte (CD14, FEGR3A), myeloid dendritic cells (mDC) (CD1C), plasmacytoid dendritic cells (pDC) (IL3RA), and plasma cells (PC) (IGKC), megakaryocyte (MYL9), cycling cells (MKI67) and erythrocyte (HBB) (Figure 1B-C, Figure S1A-S1B). By visual inspection, the data integration was efficient and showed no significant batch-effect (Figure S1C). Erythrocytes were not included in subsequent analysis and cycling cells were reclustered into cycling T, cycling PC and cycling NK cells based on specific markers (Figure S1D-S1E). This dataset indicated significantly dysregulated peripheral immune landscapes in COVID-19 patients compared to health controls, especially among those severe cases (Figure 1D). The most prominent changes included an expansion of monocyte and cycling T cells, and a reduction of NK, T and mDC populations, thus resulting in largely increased monocyte/T-cell ratios in COVID-19 patients (Figure 1E-1F). The frequency of pDC was also decreased in severe COVID-19, although the difference was not statistically significant. Together, these data show that SARS-

## Remodeling of circulating myeloid cell populations in patients with COVID-19

CoV-2 infection greatly perturbs the blood immune cell compartments, particularly in those with

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

We observed that the proportions of monocytes were increased in COVID-19 patients, especially in those with severe diseases. To further understand the remodeling of myeloid cell compartment, we reclustered myeloid cells and identified five distinct cell types including CD14<sup>+</sup> classic monocyte, CD14<sup>+</sup>CD16<sup>+</sup> intermediate monocytes, CD16<sup>+</sup> non-classic monocytes, DC1 and DC2 (Figure 2A and Figure S2A). The composition of myeloid cells in severe COVID-19 patients differed significantly from that of mild cases and controls. Proportion of CD14<sup>+</sup> monocyte increased significantly in severe COVID-19 compared to that in mild COVID-19 and control group, whereas those of CD16<sup>+</sup> non-classical monocyte (vs. controls), CD14<sup>+</sup>CD16<sup>+</sup> monocytes (vs. mild COVID-19) and DC2 significantly (vs. mild COVID-19 & controls) decreased in severe COVID-19 (Figure 2B-2C).

CD14<sup>+</sup> monocytes represent the major peripheral myeloid cell type and differential UMAP projection patterns of CD14<sup>+</sup> monocytes between COVID-19 and controls (Figure 2B) indicated perturbed transcriptome features. Among the differentially expressed genes (DEGs) in CD14<sup>+</sup> monocytes, we found 116 and 134 upregulated genes in mild COVID-19 and severe COVID-19 cases compared to controls, versus only 74 upregulated genes in comparison between two COVID-19 groups. In contrast, we found 217 and 160 downregulated genes in severe COVID-19 compared to controls or mild cases respectively, versus only 104 downregulated genes in comparison between mild COVID-19 and controls (Figure S2B and Table S1. GO terms of upregulated DEGs included response to virus, type I IFN and IFN-γ in both COVID-19 groups, and neutrophil activation and energy metabolism pathways in severe COVID-19 (Figure 2D). Unexpectedly, GO analysis of downregulated DEGs indicated deficient monocyte functions mainly in severe COVID-19 cases, such as decreased type I IFN production, cytokine secretion, chemokine production and antigen processing and presentation (Figure 2D). We further examined the DEGs associated with those GO terms. Indeed, many canonical interferon-stimulating genes (ISGs), including ISG15, IFITM1, IFITM3, MX1, IRF7, IFI27 etc., were expressed at higher levels in COVID-19 patients than controls, while the genes associated with neutrophil activation, including S100A8, S100A9, S100A12, CLU and RNASE2 etc., were expressed at higher levels in severe COVID-19 than mild COVID-19 and controls (Figure 2E). Despite of upregulated ISGs, we failed to detect higher production of type I or type III IFNs in COVID-19 than controls. Regarding the downregulated geneset, MHC class II molecules, including HLA-DQA1, HLD-DRA, HLA-DRB1, HLA-DMB, HLA-DMA, etc., and those cytokine/chemokine genes, including IL1B,

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

TNF, CCL3, CCL4 and CXCL8 were expressed at lower levels in COVID-19 patients, especially those with severe diseases (Figure 2E). Thus, those upregulated DEGs in CD14<sup>+</sup> monocytes from COVID-19 patients reflect the immune response to SARS-CoV-2 infection, while the downregulated DEGs in CD14<sup>+</sup> monocytes from patients with severe COVID-19 suggest an immune paralyzed status of those cells. MDSCs are a population of heterogeneous myeloid cells expanded during inflammatory conditions and could suppress T-cell responses<sup>21,22</sup>. In peripheral blood, monocytic MDSCs have the phenotype CD14<sup>+</sup> HLA-DR<sup>-/lo</sup>, whereas monocytes are HLA-DR<sup>+</sup> <sup>23,24</sup>. Downregulation of MHC class II molecules, increased calprotectin proteins like S100A8 and S100A9, and immune suppressive functions are reported features of MDSCs. Indeed, by their unique composite scores of MHC class II molecules (lower levels) and S100A8 family molecules (higher levels) versus those scores in mild COVID-19 and controls, we identified that the monocytes in severe COVID-19 highly resembled MDSCs (Figure 2F). Decreased levels of HLA-DR in CD14<sup>+</sup> monocyte from severe patients were further validated by flow cytometry (Figure 2G) and also reported by other studies <sup>14,18</sup>. Intriguingly. MDSCs-like scores in our study positively correlate with serum CRP, IL-6 levels and neutrophil-tolymphocyte ratio, and negatively correlate with decreased blood CD3<sup>+</sup>, CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts (Figure 2H). Together, our scRNA-seq characterization revealed a multifaceted remodeling of peripheral myeloid compartment in COVID-19 patients. While the circulating monocytes in COVID-19 patients are featured by heightened ISG responses, they produce little interferons, cytokines and chemokines. Furthermore, the combined loss of dendritic cells and emergence of monocytic MDSCs suggest their involvements in the immune paralysis of severe COVID-19 patients.

# Abnormally activated lung monocyte-macrophages in severe COVID-19

Recently, we discovered the aberrant activation of BALF monocyte-macrophages in severe COVID-19<sup>8,9</sup>. Here, to further understand the connection between the lung monocyte-macrophages and their blood counterparts and assess their differential roles in COVID-19, we studied paired BALF and blood

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

samples from 2 mild and 5 severe patients. The integration analysis of BALF and circulating myeloid cells showed clusters of neutrophil (FCGR3B), mDC (CD1C), monocyte-macrophages (CD14, FCGR3A and CD68) (Figure 3A and Figure S3A). Macrophage subset classification markers, including FCN1, SPP1 and FABP4, were differentially expressed by circulating and BALF monocytemacrophages from patients with mild or severe COVID-19(Figure 3B). Analysis of differentiation trajectory of circulating and BALF monocyte-macrophages from the same patient revealed a consensus blood-toward-BALF course (Figure 3C and Figure S3B), consistent with the recruitment to peripheral monocytes into inflammatory tissues as expected. Next, we performed transcriptome analysis of circulating and BALF monocyte-macrophages to understand their functional status. Among the DEGs, there were 524 shared upregulated genes and 501 downregulated genes in BALF monocyte-macrophages versus those in blood, identified from both mild and severe COVID-19 patients (Figure 3D and Table S2). Such a large number of DEGs suggested significant difference existed between the peripheral and lung monocyte-macrophages. Indeed, the GO analysis revealed broad activation of multiple immune pathways in BALF monocytemacrophages, including response to IFNs and cytokines, neutrophil activation and leukocyte migration, while the pathway involved in myeloid cell differentiation, ATP metabolism etc. were enriched in blood monocytes (Figure 3E). In addition, these comparisons revealed perturbed pathways in BALF monocyte-macrophages relevant to severe COVID-19. e.g. responses to hypoxia, high temperature, metal ion, wounding and Fc receptor signaling pathways were specially upregulated (Figure 3E), while pathways related to alveoli macrophage functions were downregulated, including lipid metabolism, apoptotic cell clearance and antigen presentation (Figure 3E). The representative DEGs involved in those pathways were shown in Figure S3C. Monocyte-macrophages were thought to play key roles in driving the cytokine storm underlying the development of severe COVID-19 <sup>25</sup>. Therefore, we examined the cytokine and chemokine levels in monocyte-macrophages in paired blood and BALF samples from the same patient. We found that all types of IFNs (IFNAs, IFNB, IFNG and IFNLs) were minimally expressed by monocyte-macrophages, whereas cytokines (IL1A, IL1B, IL1R2, IL1RN, IL18, IL6, TNF, IL10 and TGFB1) and multiple chemokines were highly expressed in monocyte-macrophages from BALFs but not in those from

paired blood samples (Figure 3F). Intriguingly, we observed significantly higher levels of antiinflammatory cytokines (*IL1R2*, *IL1RN* and *TGFB1*) and lower levels of *IL18* in BALF cells from
severe COVID-19 than mild cases, whereas classical pro-inflammatory cytokines (*IL1A*, *IL1B*, *IL6*and *TNF*) were comparable between the two groups (Figure 3F). In contrast, as shown in our earlier
studies, monocytes- and neutrophils- recruiting chemokines (*CCL2*, *CCL3*, *CCL4*, *CCL7*, *CCL8*, *CXCL1*, *CXCL2*, *CXCL3* and *CXCL8*) recruiting monocytes and neutrophils were highly expressed,
whereas T cell recruiting chemokines (*CXCL9* and *CXCL16*) recruiting T cells were less expressed by
monocyte-macrophages in BALFs of severe COVID-19 monocyte-macrophages than those in mild
cases (Figure 3F). The higher levels of cytokines (IL-1β and IL-6 etc.) and IL-8 in BALFs than paired
plasma was further validated at the protein levels, particularly exemplified by the extremely high levels
of IL-8 in BALFs (Figure 3G). Thus, these paired analyses revealed a restricted involvement of tissue
monocyte-macrophages in cytokine storms during severe COVID-19, through producing chemokines
and recruiting more monocytes and neutrophils, but unlikely attribute to increased production of proinflammatory cytokines.

## The dysregulated peripheral T cell compartments in COVID-19 patients

NK and T lymphocytes are important anti-viral immune cells, which are depleted in severe COVID-19 <sup>13,26</sup>. To further understand the dysregulated NK and T cell compartments, we re-clustered those cells and identified 18 subsets (Figure 4A and Figure S4A). NK cells highly expressed KLRF1, KLRC1 and KLRD1. Cycling T cells expressed MKI67. Innate-like T cells included MAIT (SLC4A10), γδ T (TRGV9) and NKT cells (CD3E, KLRF1). CD4<sup>+</sup> T cells included CD4-Naive (CCR7, SELL), CD4-LTB, CD4-GZMK, CD4-GATA3, CD4-CCR6, CD4-ICOS, CD4-GZMB, Treg-SELL and Treg-CTLA4 subsets, whereas CD8<sup>+</sup> T cells included CD8-Naive (CCR7, SELL), CD8-LTB, CD8-GZMK and CD8-GZMB subsets. Pseudo-time trajectory analysis was performed to infer lineage relationship among those CD4<sup>+</sup> and CD8<sup>+</sup> T cells subsets. Paired TCR clonotype analysis revealed increased clonal expansion along the inferred trajectories (Figure 4B). 

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

Cell density UMAP projections revealed an obviously perturbed T cell landscape in severe COVID-19 compared to mild COVID and control groups (Figure 4C). Percentages of innate-like T cells, including MAIT and NKT cells were significantly lower in severe COVID-19 than those in mild COVID-19. Percentages of CD8-Naive, CD8-GZMK and CD8-GZMB subsets were also lower in severe COVID-19 patients than those in mild cases, although the difference in CD8-GZMB comparison was not statistically significant (Figure 4D). In contrast, the percentages of several CD4<sup>+</sup> T cell subsets, including CD4-Naive, CD4-LTB, CD4-ICOS, Treg-CTLA4, as well as cycling T cells, were significantly increased in severe COVID-19 than those in mild COVID-19. The percentages of CD4-GATA3 and CD4-CCR6 also showed an increasing trend in severe COVID-19 (Figure 4D). In addition, sc-TCR analysis revealed increased clonal expansion levels in several CD4<sup>+</sup> but not CD8<sup>+</sup> T cell subsets in severe COVID-19 than those in mild cases (Figure 4E-4F). Consistently, TCR sharing analysis among different T cell subsets revealed much more active interchange between different CD4<sup>+</sup> T cell subsets and cycling T cells, but not among CD8<sup>+</sup> T cell subsets during severe COVID-19 (Figure 4G). Together, our data revealed the preferential activation of CD4<sup>+</sup> T cell responses but significant depletion of multiple innate-like T cell and CD8<sup>+</sup> T cell subsets in peripheral blood as the featured T cell perturbations in severe COVID-19. To further explore the clues of CD8<sup>+</sup> T cell lymphopenia, we conducted transcriptome comparisons of MAIT, CD8-GZMK and CD8-GZMB subsets between the patients and control groups (Figure S4C and Table S3). There was no evidence of T cell exhaustion, activation of cell death pathways and cytokine productions in those cells from COVID-19 patients, although the pathways related to virus infection and IFNs responses were identified (Figure S4D). Similar findings were also noticed by other groups<sup>16</sup>; thus, exhaustion and cell death are unlikely the major causes for T cell loss during COVID-19.

# Tracking T cell function and migration across peripheral blood and BALFs

We sought to study T cell movement from blood to BALFs in paired samples from COVID-19 patients. First, we integrated data of NK & T cells from PBMC and BALF. Cells were re-clustered into 9 major types, including NK cells, MAIT, CD4 Naive, CD4 Tm, Treg, CD8 Naive, CD8 Tm, CD8 IL7R and Cycling T cells (Figure 5A and Figure S5A). PBMC included plenty of naive CD4<sup>+</sup> and CD8<sup>+</sup> T cells,

in contrast there were fewer naive T cells in BALFs, which were mainly composed of NK cells, CD4 Tm, CD8 Tm and cycling T cells (Figure 5B). We performed gene expression analysis to determine the functional divergence of NK and T cells across the peripheral blood and BALFs (Table S4. Compared with peripheral counterparts, we observed that response to virus, type I IFN and IFN-y were commonly activated in NK, CD4 Tm and CD8 Tm cells from BALFs (Figure S5B). We also noticed higher levels of cytokines including IFNG, TNF, CSF1, TNFSF10 and TNFSF13B; chemokines including CCL3, CCL4 and CCL5; IL-15 signaling modules including IL15RA, IL2RB, IL2RG, JAK1 and STAT3 in BALF cells (Figure 5C). However, the levels of other T cell relevant cytokines, including IL4, IL5, IL10, IL13, IL17A, IL17F, IL21, IL25 and IL33 were not detected in either blood or BALFs (Figure S5C). Next, we utilized the TCR clonotype information to track the migrating T cells in blood and BALF compartment. The T cell clonal expansion status and clonotype sharing were assessed in patients with paired blood and BALF samples (Figure 5D-5E). Interestingly, considerable proportion of BALF T cells belonging to CD8 Tm, CD8 CTL and cycling T cells subsets, could trace their clonotypes back to the paired blood counterparts, especially in those patients with severe COVID-19 (Figure 5F). Here, only two mild cases (M1 and M2) had paired blood and BALF samples for the analysis, and it showed a lower degree of clonotype sharing across the two compartments (Figure 5F). The higher levels of chemokines from the lung of severe COVID-19 is likely to lead to increased T cell infiltration. To assess the functional adaptation of migrating T cells, we performed transcriptional analysis between blood vs. BALF T cells derived from the same T-cell clonotypes (Figure 5H). We found increased expression of ISGs, CCL4, CXCR4, CXCR6, CD69 and GNLY etc. in BALF cells than those in blood, consistent with an activated and tissue resident phenotype. (Figure 5G and Table S5) Together, these data revealed the active recruitment and peculiar activation of peripheral T cells in human lungs infected by SARS-CoV-2.

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

**Discussion** 

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

The scRNA-seq has been recently been applied to study host immune response in COVID-19 by us and others 8,9,13,17-19. Although these studies helped to reveal several aspects of the COVID-19 pathogenesis, a complete picture has yet been generated. Here, we integrated scRNA-seq analysis of paired blood and BALFs, depicted unprecedented details about the altered immune cell landscape in COVID-19 patients, increasing our mechanistic and systemic understanding of COVID-19 immunopathogenesis, such as cytokine storm and lymphopenia. IFN production is stunted in SARS-CoV-2 infected cells and COVID-19 patients <sup>7,27</sup>. Consistent with these earlier reports, here we found that although ISGs in COVID-19 patients were induced in monocyte-macrophages, neither type I or type III IFNs were produced. However, the higher levels of ISGs in monocyte-macrophages and T cells from mild cases than those in severe COVID-19, still supported a heightened IFN responses linked to resolving the diseases. It is unclear what causes the imbalance of inflammation and IFN production in COVID-19, we assume that the loss of pDCs in severe cases may partly contribute to the diminished IFN production. Notably, in contrast to their blood counterparts, monocyte-macrophages in paired BALFs produced extremely higher levels of cytokines and chemokines, especially from those severe COVID-19 patients. Thus, massive tissue-resident production of cytokines / chemokines and lack of IFN induction suggest a crucial role played by local but not circulating monocyte-macrophages in fueling the cytokine storm during severe COVID-19. Previously, several studies have reported that MHC class II molecules were downregulated in blood monocytes 4,14,18 in patients with severe COVID-19, however, there was still no consensus on the upregulated genes. We found here that genes related to neutrophil activation, including S100A8, S100A9 and S100A12, were expressed at higher levels in severe COVID-19 patients than those in mild cases. Interestingly, these upregulated and downregulated genes marking monocytic MDSCs whose frequencies are known to increase during various inflammatory conditions <sup>24,25</sup>. Consistent with this immune suppressive status, we also noticed that genes related to cytokine and IFN production were downregulated as well. Thus, contradicted with the inflammatory role by peripheral myeloid cells in severe COVID-19, the loss of mDCs, emergence of MDSC-like monocytes and reduced cytokine production actually suggested a peripheral immune paralysis. Since the MDSC-scores closely

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

hyperactivation, specifically in severe COVID-19.

associated with lymphopenia and inflammation markers, we speculate a crucial role of MDSCs in dampening immune response and amplifying COVID-19 pathogenesis, which need further functional validation and clinical investigations to evaluate its significance. The lymphopenia is another prominent feature of immune perturbation of severe COVID-19<sup>2,3,16</sup>. Here, we further revealed that the COVID-19 associated lymphopenia included not only depletion of CD8<sup>+</sup> T cells, but also significant loss of innate-like T cells, including MAIT,  $\gamma\delta$  T and NKT cells, similarly reported by another study <sup>13,28</sup>. In contrast, we noticed that the frequencies of CD4<sup>+</sup> T cells among all CD3<sup>+</sup> T lymphocytes were actually increased, like Th2, Th17 and Tfh cells. Those CD4<sup>+</sup> T cell subsets were also more clonally expanded, suggesting their activation status. We suspected that the disturbed T cell compartments may contribute to COVID-19 immunopathogenesis, e.g. the impaired anti-viral responses by innate-like T cells and CD8<sup>+</sup> T cells, meanwhile amplifying inflammation and inducing aberrant antibody responses by CD4<sup>+</sup> T cells. Moreover, our transcriptional analysis dispute against the evidence of cytokine production, exhaustion or increased cell death by peripheral T cells in COVID-19 patients noted by several earlier studies <sup>26,29</sup>. Instead, current TCR tracking analysis suggested that the enhanced recruitment of peripheral CD4<sup>+</sup> and CD8<sup>+</sup> T cells into lung tissues in COVID-19 patients, where they were induced to made cytokines locally and likely contributed to cytokine storm and peripheral lymphopenia. In conclusion, we comprehensively delineated the perturbed immune landscapes during SARS-CoV-2 infections from both peripheral blood and infected lungs. These data reveal potential cellular and molecular mechanisms implicated in COVID-19 immunopathogenesis; and identify a peculiar functional dichotomy, with peripheral immune paralysis and broncho-alveolar immune

Methods

**Patients** 

Ethics statement: This study was conducted according to the ethical principles of the Declaration of

Helsinki. Ethical approval was obtained from the Research Ethics Committee of Shenzhen Third

People's Hospital (2020-207). All participants provided written informed consent for sample

collection and subsequent analyses.

Thirteen COVID-19 patients were enrolled in this study at the Shenzhen Third People's Hospital.

Metadata and patients' samples were collected similarly as previously described 8: The severity of

COVID-19 was categorized to be mild, moderate, severe and critical according to the "Diagnosis and

Treatment Protocol of COVID-19 (the 7th Tentative Version)" by National Health Commission of

China (http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml). In

this study, we grouped patients with mild and moderate COVID-19 as the mild group, and included

those with severe and critical diseases as the severe group. Three healthy subjects were enrolled as the

control group.

qRT-PCR assay for SARS-CoV-2 RNA

In clinical practice, nasal swab, throat swab, sputum, anal swab or BALF could be collected for the

SARS-CoV-2 nucleic acid assays. Total nucleic acid was extracted from the samples using the

QIAamp RNA Viral kit (Qiagen) and the qRT-PCR was performed using a China Food and Drug

Administration-approved commercial kit specific for SARS-CoV-2 detection (GeneoDX). Each qRT-

PCR assay provided a threshold cycle (Ct) value. The specimens were considered positive if the Ct

value was  $\leq 37$ , and otherwise it was negative. Specimens with a Ct value > 37 were repeated. The

specimen was considered positive if the repeat results were the same as the initial result or between 37

and 40. If the repeat Ct was undetectable, the specimen was considered to be negative.

Immune cell isolation

For harvesting BALF cells, freshly obtained BALF was placed on ice and processed within 2 hours in

BSL-3 laboratory. By passing BALF through a 100 µm nylon cell strainer to filter out cell aggregates

and debris, the remaining fluid was centrifuged and the cell pellets were re-suspended in the cooled

RPMI 1640 complete medium. For PBMC isolation, immune cells from peripheral blood were isolated

by ficoll-hypaque density gradient centrifugation protocol. For subsequent study, the isolated cells

were counted in 0.4% trypan blued, centrifuged and re-suspended at the concentration of  $2 \times 10^6$  /ml.

Cytokines measurement by cytometric bead array

Twelve cytokines including IL-1β, IL-6 and IL-8 etc. were detected according to the instruction (Uni-

medica, Shenzhen, China, Cat. No. 503022). In brief, the supernatant was taken from BALF after 10

min centrifugation at 1,000g. Afterwards, 25 µl Sonicate Beads, 25 µl BALF supernatant or plasma,

and 25µl of Detection Antibodies were mixed and placed on a shaker at 500 rpm for 2 hours at room

temperature. Then 25 µl of SA-PE was added to each tube directly. The tubes were then placed on a

shaker at 500 rpm for 30 minutes. The data were obtained by flow cytometry (Canto II, BD) and were

analyzed use LEGENDplex v8.0 (VigeneTech Inc.).

Flow cytometry

For cell-surface labeling,  $1 \times 10^6$  cells were blocked with Fc-block reagent (BD Biosciences). Then, the

following antibodies were added and incubated for 30 min, including anti-CD3 (BioLegend, HIT3a),

anti-CD14 (BioLegend, 63D3), anti-HLA-DR (BioLegend, L243), and anti-CD45 (BioLegend, 2D1).

After incubation, the samples were washed and reconstituted in PBS for flow cytometric analysis on a

FACSCanto II flow cytometer.

**ScRNA-seq library construction** 

The scRNA-seq libraries were prepared with Chromium Single Cell VDJ Reagent Kits v3 (10x

Genomics; PN-1000006, PN-1000014, PN-1000020, PN-1000005) following the manufacturer's

instruction. Briefly, Gel bead in Emulsion (GEM) are generated by combining barcoded Gel Beads, a

Master Mix containing 20,000 cells, and Partitioning Oil onto Chromium Chip B. Reverse

transcription takes place inside each GEM, after which cDNAs are pooled together for amplification

and library construction. The resulting library products consist of Illumina adapters and sample indices,

allowing pooling and sequencing of multiple libraries on the next-generation short read sequencer.

ScRNA-seq data processing, cell clustering and dimension reduction

We aligned the sequenced reads against GRCh38 human reference genome by Cell Ranger (version

3.1.0, 10x genomics). To remove potential ambient RNAs, we used the remove-background function

in CellBender <sup>30</sup>, which removes ambient RNA contamination and random barcode swapping from the

raw UMI-based scRNA-seq data. Quality of cells were further assessed by the following criteria: 1)

The number of sequenced genes is 200 to 6,000; 2) The total number of UMI per cells is greater than

1,000; 3) The percentage of mitochondrial RNA is less than 15% per cell.

Data integration, cell clustering and dimension reduction were performed by Seurat (version 3)<sup>31</sup>. First,

we identified 2,000 highly variable genes (HVGs) which were used for the following analysis using

FindVariableFeatures function. Next, we integrated different samples by IntegrateData function,

which eliminates technical or batch effect by canonical correlation analysis (CCA). Using those HVGs,

we calculate a PCA matrix with the top 50 components by RunPCA function. The cells were then

clustered by FindClusters function after building nearest neighbor graph using FindNeighbors function.

The cluster-specific marker genes were identified by FindMarkers function using MAST algorithm.

The clustered cells were then projected into a two-dimension space for visualization by a non-linear

dimensional reduction method RunUMAP in Seurat package.

Integrated analysis of peripheral myeloid, NK and T cells

For cells in PBMCs, we integrated the myeloid compartment including mDC and monocytes, or NK

and T cells using the similar aforementioned procedure. We re-clustered the myeloid or NK and T

cells using the top 20 dimensions of PCA with default parameters. To obtain high resolution cell

clusters for each subset, we set the parameter resolution to 1.2. The cell clusters were annotated by

canonical markers.

Integrated analysis of myeloid, NK and T cells from PBMC and BALF

Myeloid or NK and T cells from PBMC and BALF were integrated separately. For myeloid cells, we

extracted macrophage and mDC cells in BALF, and monocyte and mDC in PBMC from the

corresponding raw count matrix. The extracted cells were integrated using CCA in Seurat (version 3)

as mentioned above. For clustering, the resolution parameter was set to 0.6. Similarly, we extracted

NK and T cells in BALF and in PBMC from the corresponding raw count matrix. The extracted cells

were integrated using CCA in Seurat (version 3) as mentioned above. For clustering, the resolution

parameter was set to 1.5.

Analysis of differentially expressed genes

FindMarkers function in Seurat (version 3) with MAST algorithm was used to analyze differentially

expressed genes (DEGs). For each pairwise comparison, we run FindMarkers function with parameters

of test.use='MAST'. The overlap of differentiated expressed genes among different comparisons were

shown by venn diagram. Genes were defined as significant up regulated if average natural logarithm

fold change > 0.25 and adjusted P < 0.01. The genes with natural logarithm fold change < -0.25 and

adjusted P < 0.01 were considered significantly down regulated. The genes shown on the heatmap

having natural logarithm fold change < -0.41 or > 0.41 and adjusted P < 0.01.

Gene ontology annotation

ClusterProfiler <sup>32</sup> in R was used to perform GO term enrichment analysis for the significantly up-

regulated and down-regulated genes. Only GO term of Biological Process (BP) was displayed.

Calculation of composite score of MHC class II molecules and calprotectin proteins

Composite signature scores of MHC class II molecules and calprotectin proteins of each peripheral

CD14<sup>+</sup> monocytes were calculated using "AddModuleScore" function implemented in the Seurat

package. MHC class II score was calculated using the following genes, i.e., HLA-DMA, HLA-DMB,

HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRA, HLA-DRB1, and HLA-DRB5.

Calprotectin protein score was calculated using genes including S100A1, S100A2, S100A3, S100A4,

S100A5, S100A6, S100A7, S100A7A, S100A7L2, S100A7P1, S100A7P2, S100A8, S100A9, S100A10,

S100A11, S100A12, S100A13, S100A14, S100A15A, S100A16, S100B, S100G, S100P, and S100Z. The

correlations between MDSC-like scores ("Calprotectin protein score" minus "MHC class II score") and plasma IL6, CRP levels, and the blood neutrophil / CD3 / CD4 / CD8 cell counts, were calculated using GraphPad Prism 8.4.2. Lines were fitted using the simple linear regression method.

Pseudotime trajectory analysis

Trajectories analysis was performed using slingshot <sup>33</sup> for monocyte-macrophages and T cells separately. For T cells in PBMC, naive CD4 and CD8 T cells were set as the start point for CD4<sup>+</sup> T cells and CD8<sup>+</sup> T differentiation trajectory, respectively. For integrated analysis of monocyte-macrophages in PBMC and BALF, we deduced the cell trajectory for each individual using the peripheral monocytes as the start point.

Single-cell TCR analysis

The amino acid and nucleotide sequence of TCR chains were assembled and annotated by cellranger vdj function in CellRanger (version 3.1.0). Only cells with paired TCR $\alpha$  and TCR $\beta$  chains were included in clonotype analysis. Cells sharing the same TCR $\alpha$ - and TCR $\beta$ -CDR3 amino acid sequences were assigned to the same TCR clonotype. We assessed the TCR expansion, TCR transition among cell types and TCR migration between PBMC and BALF using R package STARTRAC (version 0.1.0) <sup>34</sup>. TCR migration between PBMC and BALF were shown using circos software <sup>35</sup>.

**Statistics** 

The Student's t-test (t.test in R, two-sided, unadjusted for multiple comparisons) was used for pairwise comparisons of the cell proportions between different groups. Statistical difference of TCR expansion index and migration index, between mild and severe disease group, were calculated using t.test in R. Statistical difference of cytokines level between BALF and Blood in Figure 3G were calculated using two-sided wilcox.test in R.

Reference:

1. Guan, W.J., *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* **382**, 1708-1720 (2020).

- 2. Zhou, F., *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* **395**, 1054-1062 (2020).
- 3. Chen, R., *et al.* Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. *J Allergy Clin Immunol* (2020).
- 4. Xu, X., *et al.* Effective treatment of severe COVID-19 patients with tocilizumab. *Proc Natl Acad Sci U S A* **117**, 10970-10975 (2020).
- 5. Tay, M.Z., Poh, C.M., Renia, L., MacAry, P.A. & Ng, L.F.P. The trinity of COVID-19: immunity, inflammation and intervention. *Nat Rev Immunol* **20**, 363-374 (2020).
- 6. Roschewski, M., *et al.* Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. *Sci Immunol* **5**(2020).
- 7. Blanco-Melo, D., *et al.* Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. *Cell* **181**, 1036-1045 e1039 (2020).
- 8. Liao, M., et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. *Nat Med* (2020).
- 9. Bost, P., et al. Host-Viral Infection Maps Reveal Signatures of Severe COVID-19 Patients. Cell (2020).
- 10. Fan Wu, A.W., Mei Liu, Qimin Wang, Jun Chen, Shuai Xia, Yun Ling, Yuling Zhang, Jingna Xun, Lu Lu, Shibo Jiang, Hongzhou Lu, Yumei Wen, Jinghe Huang. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *medRxiv preprint doi:* <a href="https://doi.org/10.1101/2020.03.30.20047365">https://doi.org/10.1101/2020.03.30.20047365</a> (2020).
- 11. Ni, L., *et al.* Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals. *Immunity* (2020).
- 12. Grifoni, A., et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* (2020).
- 13. Wen, W., et al. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. *Cell Discov* **6**, 31 (2020).
- 14. Giamarellos-Bourboulis, E.J., *et al.* Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. *Cell Host Microbe* (2020).
- 15. Ildefonso Sanchez-Cerrillo, P.L., Beatriz Aldave, Santiago Sanchez-Alonso, Ana Sanchez-Azofra, Ana Marcos-Jimenez, Elena Avalos, Ana Alcaraz-Serna, Ignacio de los Santos, Tamara Mateu-Albero, Laura Esparcia, Celia Lopez-Sanz, Pedro Martinez-Fleta, Ligia Gabrie, Luciana del Campo Guerola, Maria Jose Calzada, Isidoro Gonzalez-Alvaro, Arantzazu Alfranca, Francisco Sanchez-Madrid, Cecilia Munoz-Calleja, Joan B Soriano, Julio Ancochea, Enrique Martin-Gayo. Differential Redistribution of Activated Monocyte and Dendritic Cell Subsets to the Lung Associates with Severity of COVID-19. *medRxiv* 2020.05.13.20100925; doi: <a href="https://doi.org/10.1101/2020.05.13.20100925">https://doi.org/10.1101/2020.05.13.20100925</a> (2020).
- Divij Mathew, J.R.G., Amy E. Baxter, Allison R. Greenplate, Jennifer E. Wu, Cécile Alanio, Derek A. Oldridge, Leticia Kuri-Cervantes, M. Betina Pampena, Kurt D' Andrea, Sasikanth Manne, Zeyu Chen, Yinghui Jane Huang, John P. Reilly, Ariel R Weisman, Caroline A.G. Ittner, Oliva Kuthuru, Jeanette Dougherty, Kito Nzingha, Nicholas Han, Justin Kim, Ajinkya Pattekar, Eileen C. Goodwin, Elizabeth M. Anderson, Madison E. Weirick, Sigrid Gouma, Claudia P. Arevalo, Marcus J. Bolton, Fang Chen, Simon F. Lacey, Scott E. Hensley, Sokratis Apostolidis, Alexander C. Huang, Laura A. Vella, The UPenn COVID Processing Unit, Michael R. Betts, Nuala J. Meyer, E. John Wherry. Deep immune profiling of COVID-19 patients reveals patient heterogeneity and distinct immunotypes with implications for therapeutic interventions. *bioRxiv* 2020.05.20.106401; doi: https://doi.org/10.1101/2020.05.20.106401 (2020).
- 17. Robert Lorenz Chua, S.L., Saskia Trump, Bianca P Hennig, Daniel Wendisch, Fabian Pott, Olivia Debnath,

Loreen Thürmann, Florian Kurth, Julia Kazmierski, Bernd Timmermann, Sven Twardziok, Stefan Schneider, Felix Machleidt, Holger Müller-Redetzky, Alexander Krannich, Sein Schmidt, Felix Balzer, Johannes Liebig, Jennifer Loske, Jürgen Eils, Naveed Ishaque, Christof von Kalle, Andreas Hocke, Martin Witzenrath, Christine Goffinet, Christian Drosten, Sven Laudi, Irina Lehmann, Christian Conrad, Leif-Erik Sander, Roland Eils. Cross-talk between the airway epithelium and activated immune cells defines severity in COVID-19. *medRxiv 2020.04.29.20084327*; doi: https://doi.org/10.1101/2020.04.29.20084327 (2020).

- 18. Aaron J. Wilk, A.R., Nancy Q. Zhao, Jonasel Roque, Giovanny J. Martínez-Colón, Julia L. McKechnie, Geoffrey T. Ivison, Thanmayi Ranganath, Rosemary Vergara, Taylor Hollis, Laura J. Simpson, Philip Grant, Aruna Subramanian, Angela J. Rogers Catherine A. Blish A single-cell atlas of the peripheral immune response in patients with severe COVID-19. *Nature Medicine* (2020).
- 19. Philip A Mudd, J.C.C., Jackson S Turner, Aisha Souquette, Daniel Reynolds, Diane Bender, James P. Bosanquet, Nitin J. Anand, David A. Striker, R. Scott Martin, Adrianus C. M. Boon, Stacey L. House, Kenneth E. Remy, Richard S. Hotchkiss, Rachel M. Presti, Jane A. OHalloran, William G. Powderly, Paul G. Thomas, Ali H. Ellebedy. Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe Disease. *medRxiv* 2020.05.28.20115667; doi: https://doi.org/10.1101/2020.05.28.20115667 (2020).
- 20. Weiss, P. & Murdoch, D.R. Clinical course and mortality risk of severe COVID-19. *Lancet* **395**, 1014-1015 (2020).
- 21. Gabrilovich, D.I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol* **9**, 162-174 (2009).
- 22. Veglia, F., Perego, M. & Gabrilovich, D. Myeloid-derived suppressor cells coming of age. *Nat Immunol* **19**, 108-119 (2018).
- 23. Mengos, A.E., Gastineau, D.A. & Gustafson, M.P. The CD14(+)HLA-DR(lo/neg) Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy. *Front Immunol* **10**, 1147 (2019).
- 24. Bronte, V., *et al.* Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nat Commun* **7**, 12150 (2016).
- 25. Merad, M. & Martin, J.C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. *Nat Rev Immunol* **20**, 355-362 (2020).
- 26. Yonggang Zhou, B.F., Xiaohu Zheng, Dongsheng Wang, Changcheng Zhao, Yingjie qi, Rui Sun, Zhigang Tian, Xiaoling Xu, Haiming Wei Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. *National Science Review* (2020).
- 27. Jéro me Hadjadj, Nader Yatim,\*, Laura Barnabei, Aurélien Corneau, Jeremy Boussier, Hélène Péré, Bruno Charbit, Vincent Bondet, Camille Chenevier- Gobeaux, Paul Breillat, Nicolas Carlier, Rémy Gauzit, Caroline Morbieu, Frédéric Pène, Nathalie Marin, Nicolas Roche, Tali-Anne Szwebel, Nikai a Smith, Sarah H Merkling, Jean-Marc Treluyer, David Verer, Luc Mouthon, Catherine Blanc, Pierre-Louis Tharaux, Flore Rozenberg, Alain Fischer, Darragh Duffy#, Frédéric Rieux-Laucat#, Solen Kernéis# and Benjamin Terrier#. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients. medRxiv preprint doi: https://doi.org/10.1101/2020.04.19.20068015 (2020).
- 28. Youenn Jouan, A.G., Loic Gonzalez, Yonatan Perez, Stephan Ehrmann, Marion Ferreira, Thomas Daix, Robin Jeannet, Bruno Francois, Pierre-Francois Dequin, Mustapha Si-Tahar, Thomas Baranek, Christophe Paget. Functional alteration of innate T cells in critically ill Covid-19 patients. *medRxiv 2020.05.03.20089300*; *doi: https://doi.org/10.1101/2020.05.03.20089300* (2020).
- 29. Bo Diao, C.W., Yingjun Tan, Xiewan Chen, Ying Liu, Lifeng Ning, Li Chen, Min Li, Yueping Liu, Gang Wang, Zilin Yuan, Zeqing Feng, Yuzhang Wu, Yongwen Chen. Reduction and Functional Exhaustion of T Cells in

- Patients with Coronavirus Disease 2019 (COVID-19). *medRxiv* 2020.02.18.20024364; doi: https://doi.org/10.1101/2020.02.18.20024364 (2020).
- 30. Stephen J. Fleming, V.O.P.C.M., Mehrtash Babadi. CellBender remove-background: a deep generative model for unsupervised removal of background noise from scRNA-seq datasets. *bioRxiv preprint doi:* https://doi.org/10.1101/791699. (2020).
- 31. Stuart, T., et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888-1902 e1821 (2019).
- 32. Yu, G., Wang, L.G., Han, Y. & He, Q.Y. clusterProfiler: an R package for comparing biological themes among gene clusters. *OMICS* **16**, 284-287 (2012).
- 33. Street, K., *et al.* Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics. *BMC Genomics* **19**, 477 (2018).
- 34. Zhang, L., *et al.* Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. *Nature* **564**, 268-272 (2018).
- 35. Krzywinski, M., *et al.* Circos: an information aesthetic for comparative genomics. *Genome Res* **19**, 1639-1645 (2009).

Table 1. Clinical data of the enrolled COVID-19 patients and healthy controls examined by scRNA-seq

Sample NO.	S1	S2	<b>S</b> 3	S4	S5	S6	S7	S8	M1	M2	М3	M4	M5	H1	H2	H3
Severity	severe	severe	severe	severe	severe	severe	severe	severe	mild	mild	mild	mild	mild	HC	HC	НС
Age	73	46	67	65	62	57	63	66	35	36	42	49	32	66	36	31
Gender	Male	Male	Male	Female	Male	Female	Male	Male	Male	Male	Male	Female	Female	Female	Female	Male
Symptom onset day	2020/1/20	2020/1/21	2020/1/17	2020/1/4	2020/1/11	2020/1/21	2020/1/8	2020/1/3	2020/1/9	2020/1/9	2020/1/18	2020/1/22	2020/1/21			
First symptom	Fever	Fever/Cough	Fever/diarrhea	Fever/Cough	Fever/Cough	Cough	Fever/Cough	Fever	Cough	Cough	Fever/Cough	Fever/Cough	Fever			
Hospitalization date	2020/1/22	2020/1/22	2020/1/22	2020/1/20	2020/1/15	2020/1/23	2020/1/15	2020/1/11	2020/1/15	2020/1/16	2020/1/21	2020/1/23	2020/1/23			
Chronic basic disease	none	none	Bronchitis	diabetes	none	none	COPD	hyperpression	none	none	None	None				
CoV-RNA	+	+	+	+	+	+	+	+	+	+	-	-	-	+	-	+
Influenza A virus	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Influenza B virus	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Respiratory syncytial virus	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Adenovirus	- Bilateral	- Unilateral	- Bilateral	- Unilateral	- Bilateral	- Bilateral	- Bilateral	- Bilaeral	- Bilateral	- Bilateral	- Bilaeral	- Bilaeral	- Unilateral	-	-	-
CT finding PBMC	pneumonia	pneumonia	pneumonia	pneumonia	pneumonia	pneumonia	pneumonia	pneumonia	pneumonia	pneumonia	pneumonia	pneumonia	pneumonia			
sampling date	2020/2/2	2020/2/2	2020/1/28	2020/1/28	2020/1/30	2020/1/29	2020/1/29	2020/1/31	2020/1/29	2020/1/22	2020/1/23	2020/1/28	2020/1/28			
Outcome-date	Cure/2020/2/20	Cure/2020/3/8	Cure/2020/3/20	Cure/2020/3/9	Cure/2020/2/27	Cure/2020/3/7	Dead/2020/2/16	Dead/2020/2/16	Cure/2020/2/3	Cure/2020/1/27	Cure/2020/2/3	Cure/2020/2/8	Cure/2020/2/9			
IL6 (pg/ml)	35.54	17.99	36.14	14.61	69.18	22.87	225.3	353.2	4.43	1.92	18.33	35.2	4.59			
CRP (pg/ml)	6.94	50.63	112.78	2.4	88.88	7.86	33.11	189.23	6.75	1.31	12.75	60.01	8.63			
WBC(109/L)	5.75	12.42	11.47	9.59	7.13	32.04	11.47	7.24	5.38		4.13	5.67	4.55			
NEUT(109/L)	5.49	11.5	10.52	8.62	5.45	29.19	10.11	5.56	2.64		2.58	3.77	3.02			
LYMPH(109/L)	0.16	0.33	0.46	0.59	0.82	1.45	0.88	0.78	2.14		1.09	1.19	1.09			
MONO(109/L)	0.1	0.58	0.47	0.37	0.79	1.39	0.45	0.18	0.44		0.46	0.59	0.31			
NEUT/LYMPH	34.3	34.8	22.9	14.6	6.6	20.1	11.5	7.1	1.2		2.4	3.2	2.8			
CD3 (cells/ul)	66	92	141	201	427	744	268	629	1782		527	1258	1261			
CD4 (cells/ul)	59	58	93	149	354	563	181	495	1141		301	684	671			
CD8 (cells/ul)	5	30	37	45	66	166	80	128	566		204	420	565			

### Figure 1 Single-cell analysis of peripheral blood mononuclear cells from patients with COVID-19

- (A) The carton outlines the study design. PBMC and BALF cells from COVID-19 patients and healthy controls were collected for scRNA-seq characterization using the 10x Genomics platform. Number of samples, analyzed cells, and samples with PBMC and BALF cells simultaneously collected from the same patient are indicated.
- (B) The UMAP projection of the combined PBMCs scRNA-seq dataset, identifies 9 major cell types. PC stands for plasma cells.
- (C) The specific markers for identifying each immune cell types in (B) are indicated.
- (D) Density plots shows the UMAP projection of PBMCs from COVID-19 patients and controls.
- (E) The bar plot shows the proportions of each cell types in PBMCs from individual subjects. The cell numbers and ratios of monocyte / T-cells are listed to the right-side.
- (F) Comparisons of percentages of each cell types in PBMCs (Cycling cells were re-clustered into T and PC subsets) between the two COVID-19 groups and controls (two-sided Student's *t*-test, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.

### Figure 2 Single-cell analysis of peripheral myeloid cell compartments in patients with COVID-19

- (A) UMAP plot of the five types of myeloid cells in PBMCs.
- (B) Density plots show the UMAP projection of peripheral myeloid cells from COVID-19 patients and controls.
- (C) Comparisons of percentages of each peripheral myeloid cell types between the two COVID-19 groups and controls (two-sided Student's *t*-test, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001).
- (D) Enrichment of GO biological process (BP) terms for up-regulated genes (left) and down-regulated genes (right) in blood CD14<sup>+</sup> monocyte comparisons between mild and HC (M vs H), severe and HC (S vs H), and severe and mild groups (S vs M). (representative terms are shown, adjusted p < 0.01 as indicated by the colored bar).
- (E) The heatmaps show the selected differentially expressed genes and their associated GO terms as indicated in (D). (Natural logarithm fold change > 0.41 or < -0.41, adjusted p < 0.01).
- (F) Density plots show the composite MHC class II signature scores and calprotectin signature scores of peripheral CD14<sup>+</sup> monocytes in 2D maps. The horizontal and vertical lines separating the four quadrants represent the median scores of all CD14<sup>+</sup> monocytes. The percentages of cells in each quadrant are indicated.
- (G) The Pearson correlation of "MDSC-like signature score" and plasma CRP, IL-6 levels, blood neutrophil, CD3<sup>+</sup>, CD4<sup>+</sup> and CD8<sup>+</sup> T cell counts.
- (H) Left panel shows the representative flow cytometric data of HLA-DR expression on CD14<sup>+</sup> and CD14<sup>-</sup> PBMCs. Right plot shows the summarized data from more subjects (two-sided Student's *t*-test).

### Figure 3 Abnormally activated lung monocyte-macrophages in severe COVID-19

- (A) The myeloid cell data from 2 mild and 5 severe COVID-19 patients who had paired PBMC and BALF samples, were integrated and presented on the UMAP.
- (B) The expression of monocyte-macrophage markers FCN1, SPP1 and FABP4 were projected to UMAP from (A).
- (C) Differentiation trajectory of the blood monocytes and BALF monocyte-macrophages from two representative COVID-19 patients, analyzed independently.
- (D) Venn diagram shows the number of up-regulated and down-regulated DEGs in monocyte-macrophages comparisons as indicated. BM: BALF of mild cases; BS: BALF of severe cases; PM: Peripheral cells of mild cases; PS: Peripheral cells of severe cases. (Natural logarithm fold change > 0.41 or < -0.41, adjust p < 0.01)
- (E) Enrichment of GO biological process (BP) terms for up-regulated genes (left) and down-regulated genes (right) in monocyte-macrophage comparisons as indicated. (Selected terms are shown, adjusted p value is indicated by the

colored bar).

- (F) Heatmaps show the expression of selected interferon, cytokine and chemokine genes in paired blood and BALF monocyte-macrophages derived from the same patient. Stars indicate that the genes are differentially expressed in BALF monocyte-macrophages between mild and severe COVID-19. Purple and green stars show the gene expression are significantly upregulated in severe COVID-19 and mild COVID-19 group respectively (MAST; p < 0.01).
- (G) The levels of selected cytokines and chemokines in paired BALF and plasma samples were measured by CBA (two-sided Wilcoxon test between BALF and PBMC of severe patients).

## Figure 4 Single-cell analysis of peripheral NK and T cell compartments in patients with COVID-19

- (A) UMAP plot of the 18 subsets of NK and T cells in PBMCs.
- (B) Pseudo-time differentiation trajectory of the peripheral CD4<sup>+</sup> and CD8<sup>+</sup> T cells subsets performed by slingshot. The bar plots in the corner shows the percentages of clonally expanded cells in each T cell subsets.
- (C) Density plots show the UMAP projection of peripheral NK and T cells from COVID-19 patients and controls.
- (D) Comparisons of percentages of each peripheral NK and T cell types between the two COVID-19 groups and controls (two-sided Student's t-test, \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001).
- (E) Clonally expanded T cells from COVID-19 patients and controls are projected into UMAP from (A).
- (F) Clonal expansion indexes of T cell subsets from COVID-19 patients and controls, are separately displayed.
- (G) T cell state transition status among any two clusters is inferred by their shared TCR clonotypes. Each T cell cluster is represented by a unique color. The numbers above the bar indicate the percentages of cells sharing TCRs in those two clusters.

### Figure 5 Tracking T cells across peripheral blood and BALFs in patients with COVID-19

- (A) The T cell data from 2 mild and 5 severe COVID-19 patients who had paired PBMC and BALF samples, were integrated and presented on the UMAP.
- (B) The percentages of each T cell subset in paired BALF (B) and PBMC (P) of the same patient are compared.
- (C) Heatmaps display the selected DEGs in NK, CD4 Tm and CD8 Tm cells in BALF (B) or PBMC (P) from the mild (M) or severe (S) COVID-19 patients. (Natural logarithm fold change > 0.41,, adjust p < 0.01).
- (D) The migration index in each T cell subset across paired PBMC and BALF from seven patients were shown (STARTRAC-migr indices).
- (E) TCR clonotypes were classified into five different types as indicated by different color bars (singleton indicates non-expanded TCR clonotype, multiplet indicates expanded TCR clonotype, dual-clone indicates those clonotype shared in paired PBMC and BALF samples). The bar plots show the percentages of different types of TCR clonotypes in different T cell subsets from paired PBMC and BALF samples.
- (F) The circus plot shows the degree of TCR clonotype sharing across different T cell subsets in PBMC and BALF from mild and severe COVID-19 groups.
- (G) Heatmap shows the selected DEGs in each T cell clones derived from the top 13 TCR clonotypes shared across PBMC versus BALF compartments. (Natural logarithm fold change > 0.41, adjust p < 0.01).
- (H) The V, J genes of the TCR  $\alpha$  and  $\beta$  chains of the top 13 dual clonotypes are listed, the amino acid sequences of their CDR3 are shown.

Fig.1




Fig.2




Fig.3




Fig.4




Fig.5

